Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | Impact of CD8+ T cell activation in the presence of TLR agonists

Douglas G. McNeel • 12 Nov 2021
SITC 2021
General

Douglas G. McNeel, MD, PhD, University of Wisconsin Carbone Cancer Center, University of Wisconsin, Madison, WI, discusses the results from a study investigating the impact of CD8+ T-cell activation in the presence of multiple toll-like receptor (TLR) agonists. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

More from Douglas G. McNeel

0:56
Vaccines are a promising direction for prostate cancer immunotherapy
Douglas G. McNeel • 12 Nov 2021
1:32
Combining antigen-specific vaccination and targeted radionuclide therapy in a murine prostate model
Douglas G. McNeel • 12 Nov 2021
1:30
Asessing the pTVG-HP Plasmid DNA vaccine in patients with mCRPC
Douglas G. McNeel • 12 Nov 2021
1:05
Combining a DNA vaccine with pembrolizumab for mCRPC
Douglas G. McNeel • 12 Nov 2021

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals